Wall Street fawns over the companies listed below. So why do our Motley Fool CAPS members disagree? They've tarred these stocks with one- and two-star ratings, signaling their lack of faith that the associated companies will outperform the market.

So who's got it right? The professional class of analysts, smoking stogies in their paneled offices, or a motley crew of community investors, pooling their best thoughts for others to share? We think we know who'll come out ahead. How about you?


CAPS Rating (out of 5)

Wall Street Bullish Sentiment

Orexigen Therapeutics (Nasdaq: OREX)



Research in Motion (Nasdaq: RIMM)



Tiffany (NYSE: TIF)



Source: Motley Fool CAPS.

Now, as much as we love our CAPS community, you shouldn't sell these companies short just because they've garnered the lowest opinions. Nor should you buy 'em just because Wall Street says to, either. Investing requires closer diligence on your part, so use these ratings as a launching pad for your own research.

A heavy burden
Investors tend to be optimistic. We invest in companies because we expect (or at least hope) they will be successful, which in turn will reward us. There comes a time, though, where we need to cut and run.

Obesity-drug maker Orexigen Therapeutics is doing just that, shaving off 40% of its workforce while it comes to terms with FDA demands for new tests on its therapy Contrave. The regulatory agency has determined that a whole passel of fat-fighting drugs from Orexigen, Arena Pharmaceuticals (Nasdaq: ARNA), and VIVUS (Nasdaq: VVUS) have a lot more to prove before they can reach the market. As a matter of survival, Orexigen needs to hunker down and focus on the task at hand.

CAPS member investorpatent notes that while Orexigen's management is capable and commendable, the company has a long road ahead. Only optimistic outlook could keep the stock propped up, even at these new, lower levels:

Destined to fail, pop was caused by short covering, now reality kicking in. Worth probably $1 but surely not over $3. Coming back to earth soon. No sensible investor will wait 4-5 years and heavy dillution for a dubious outcome. Only positive is honest management.

Let us know on the Orexigen Therapeutics CAPS page whether the drugmaker will detour off the road to recovery.

A fat opportunity
Although the hype surrounding the new iPhone from Verizon (NYSE: VZ) was almost palpable, and the phone company is expected to sell the new iPad, too, BlackBerry maker Research In Motion is generating some good buzz of its own with the planned launch of its Playbook tablet computer.

More importantly, CAPS member gofundoo sees the new mobile computing platform adding significantly to earnings:

The stock is Under valued and even asuming the smart phone business does not grow and stagnates which i dont think it will thanks to the new QNX Os the tablet vertical alone will add another 25-35 cents in EPS each quarter of the next year add that to the existing smart phone eps without any growth you will still end up with around 2 $a quarter in eps for the rest of next year which means 8 $a share 1 year forward earnings which shows the current price highly undervalued

Add Research In Motion to the Fool's free portfolio tracker to keep on top of how much the Playbook cuts into the iPad's market share.

Construct an argument for growth
Hermes saw sales jump 25% in 2010 and raised guidance for the coming year. LVMH Moet Hennessy Louis Vuitton -- boy, that company had better stop making acquisitions -- reported a 75% surge in profits last year, and it's feeling confident that 2011 is going to be another good year. Even Coach (NYSE: COH) is generating 19% net sales growth and 26% earnings increases.

Luxury may have hibernated during the recession, but it's back with a vengeance now. Tiffany reported some strong holiday success as well, and today is the day of l'amour -- so why are investors so down on its prospects? Perhaps because its shares have had a terrific run over the past year, rising more than 58%. With shares trading in excess of 25 times trailing earnings, the stock may seem a bit rich to some.

Not to CAPS member Torless, though, who believes the fine jeweler will continue to lead luxury goods out of the recession:

Luxury products, especially those with strongly branded names emerge first out of recession. Tiffany & Co is internationally recognized, a market leader among peers, and just announced a 400 million dollar stock buyback.

Add Tiffany to your watchlist, then head over to the Tiffany CAPS page and polish up your knowledge on this high-end opportunity.

What's wrong with that?
It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

Sign up today for the completely free service, and tell us which side of the street will be the ultimate winner.

Apple and Coach are Motley Fool Stock Advisor recommendations. The Fool has written puts on Apple. The Fool owns shares of Apple, and Coach. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.